New antithrombotic treatment strategies in interventional cardiology

Sponsored by Bayer AG

Chairpersons: R. Mehran, M. Gilard

Learning Objectives

  • To learn about new methodologies for antithrombotic treatments in PCI patients
  • To understand impact of NOACs as adjunct to cardiovascular interventions
  • To learn about novel ways of preventing atherothrombotic burden in high risk vascular patients

Presentations available when logged in:

  • Session objectives
  • TAVI: current and future perspectives for adjunctive antithrombotic therapy
  • PIONEER AF-PCI: changing clinical practice in atrial fibrillation patients undergoing PCI
  • Novel ways to reduce atherothrombotic burden in interventional cardiology
  • Session evaluation and key learnings